Edgewise Therapeutics, Inc. (EWTX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 590K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -590K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 53.52M | 55.98M | 46.86M | 42.61M | 45.96M | 45.54M | 40.43M | 38.11M | 34.75M | 33.86M | 29.45M | 25.34M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 11.46M | 12.38M | 9.38M | 9.05M | 9.2M | 9.17M | 8.21M | 7.43M | 7.06M | 6.18M | 5.67M | 5.78M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 42.65M | 43.59M | 37.48M | 33.56M | 36.76M | 36.37M | 32.22M | 30.68M | 27.69M | 27.68M | 23.79M | 19.56M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -590K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -54.12M | -55.98M | -46.86M | -42.61M | -45.96M | -45.54M | -40.43M | -38.11M | -34.75M | -33.86M | -29.45M | -25.34M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -17.75% | -22.92% | -15.89% | -11.82% | -32.24% | -34.49% | -37.28% | -50.39% | -35.2% | -53.37% | -61.27% | -53.65% |
| EBITDA | -53.52M | -57.62M | -46.34M | -42.04M | -45.41M | -44.91M | -39.83M | -37.57M | -34.23M | -33.33M | -28.95M | -24.88M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -17.88% | -28.3% | -16.33% | -11.9% | -32.65% | -34.75% | -37.56% | -51.03% | -34.42% | -51.59% | -60% | -52.28% |
| D&A (Non-Cash Add-back) | 590K | -1.64M | 523K | 567K | 554K | 629K | 602K | 534K | 525K | 533K | 497K | 461K |
| EBIT | -54.12M | -50.22M | -40.67M | -42.61M | -45.96M | -45.54M | -40.43M | -38.11M | -34.75M | -33.86M | -29.45M | -25.34M |
| Net Interest Income | 5.1M | 5.76M | 6.19M | 6.5M | 5.16M | 5.88M | 6.3M | 6.61M | 6.23M | 3.72M | 3.74M | 3.87M |
| Interest Income | 5.1M | 5.76M | 6.19M | 6.5M | 5.16M | 5.88M | 6.3M | 6.61M | 6.23M | 3.72M | 3.74M | 3.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 5.1M | 5.76M | 6.19M | 6.5M | 5.16M | 5.88M | 6.3M | 6.61M | 6.23M | 3.72M | 3.74M | 3.87M |
| Pretax Income | -49.01M | -50.22M | -40.67M | -36.12M | -40.8M | -39.66M | -34.13M | -31.5M | -28.52M | -30.14M | -25.71M | -21.47M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -49.01M | -50.22M | -40.67M | -36.12M | -40.8M | -39.66M | -34.13M | -31.5M | -28.52M | -30.14M | -25.71M | -21.47M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -20.14% | -26.61% | -19.15% | -14.66% | -43.03% | -31.58% | -32.73% | -46.71% | -24.9% | -55.26% | -46.95% | -33.62% |
| Net Income (Continuing) | -49.01M | -50.22M | -40.67M | -36.12M | -40.8M | -39.66M | -34.13M | -31.5M | -28.52M | -30.14M | -25.71M | -21.47M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 |
| EPS Growth % | -6.98% | -11.9% | -8.33% | 0% | -30.3% | 10.64% | 12.2% | 0% | -6.45% | -80.77% | -28.13% | -6.25% |
| EPS (Basic) | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 |
| Diluted Shares Outstanding | 107.12M | 102.93M | 105.49M | 104.94M | 95.13M | 92.41M | 93.81M | 93.52M | 87.57M | 64.77M | 63.46M | 63.38M |
| Basic Shares Outstanding | 107.12M | 102.93M | 105.49M | 104.94M | 95.13M | 92.41M | 93.81M | 93.52M | 87.57M | 64.77M | 63.46M | 63.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |